Abstract
Post-transplant lymphoproliferative disorder (PTLD) in the central nervous system (CNS) is a very rare complication of haematopoietic stem cell transplant (HSCT) and has a dismal prognosis. We report the successful treatment of this disorder with intrathecal rituximab therapy in two children who developed isolated CNS PTLD after HSCT. These children had failed to respond to standard chemotherapy, intravenous rituximab and EBV specific cellular therapy.
Copyright © 2011 Wiley Periodicals, Inc.
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
-
Antineoplastic Agents / administration & dosage*
-
Central Nervous System Diseases / drug therapy*
-
Central Nervous System Diseases / etiology
-
Central Nervous System Diseases / pathology
-
Child, Preschool
-
Epstein-Barr Virus Infections / drug therapy*
-
Epstein-Barr Virus Infections / etiology
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Injections, Spinal
-
Leukemia, B-Cell / drug therapy
-
Leukemia, B-Cell / etiology
-
Leukemia, B-Cell / pathology
-
Lymphohistiocytosis, Hemophagocytic / drug therapy
-
Lymphohistiocytosis, Hemophagocytic / etiology
-
Lymphohistiocytosis, Hemophagocytic / pathology
-
Lymphoproliferative Disorders / drug therapy*
-
Lymphoproliferative Disorders / etiology
-
Lymphoproliferative Disorders / pathology
-
Magnetic Resonance Imaging
-
Male
-
Rituximab
-
Virus Activation*
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab